Purchase this article with an account.
A. Y. Fong, D. T. H. Tan, L. K. H. Lee, L. Tong, A. Yang; A Randomized Controlled Trial Evaluating the Efficacy of Neurovision's Neural Vision Correction TM Technology in Enhancing Unaided Visual Acuity in Adults With Low Myopia - 1 Year Follow-up Results. Invest. Ophthalmol. Vis. Sci. 2009;50(13):3973.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To evaluate the 1 year post treatment efficacy of NeuroVision’s Neural Vision CorrectionTM (NVCTM) Technology in enhancing unaided visual acuity in adults with low myopia.
NeuroVision’s NVCTM technology is a non-invasive, patient-specific, perceptual learning program based on visual stimulation and facilitation of neural connections at the cortical level. It involves an internet-based computer generated visual training exercise regime using stimuli based on Gabor patches, to sharpen contrast sensitivity and visual acuity. A double masked randomized controlled trial was conducted to evaluate the efficacy of NVCTM technology in improving unaided visual acuity (UAVA) of low myopic patients. 84 adult low myopic patients (LMP) with SE ≤ -1.5D (mean SE -1.29D) were randomly divided into 2 groups. Group A (67 LMP) completed NVCTM treatment, Group B (17 LMP) completed sham treatment.
Mean UAVA improved by 0.183 logMar in Group A compared to 0.030 logMar in Group B. 64.2% of LMP in group A improved more than 0.2 logMar in at least one eye compared to 11.8% in Group B (p<0.0005). LMP in group A maintained 68% of the improvement in the 12 months post treatment while LMP in group B maintained 22% only.
NVCTM treatment demonstrated statistically significant UAVA improvement in adults with low myopia.
Clinical Trial: :
This PDF is available to Subscribers Only